Business / Finance

RSS

Standard Register first quarter total revenues decline 4% to $157.6M

Standard Register today announced its financial results for the first quarter 2012. The Company reported revenue of $157.6 million and a net loss of $5.1 million, or $0.18 per share. The results compare to prior year revenue of $164.9 million and net income of $0.4 million, or $0.01 per diluted share.

21 Apr 2012

UnitedHealth Group's consolidated first quarter revenues increase 7% to $27.3B

UnitedHealth Group today reported first quarter results, highlighted by strong enrollment and revenue growth in each of UnitedHealthcare's benefits businesses and well-diversified revenue growth at Optum. First quarter 2012 net earnings were $1.31 per share, with continued performance on key financial and operational measures.

19 Apr 2012

Intervertebral disc repair phase 2 trial update from Mesoblast

Global regenerative medicine company Mesoblast Limited (ASX:MSB) has announced that its Phase 2 clinical trial investigating the use of allogeneic, or off-the-shelf, Mesenchymal Precursor Cells (MPCs) for non-surgical restoration of degenerated intervertebral discs and treatment of low back pain has enrolled 50% of the total study patients. This rapid rate of enrolment attests to the major unmet medical need and to the relative simplicity of Mesoblast’s non-surgical procedure. Mesoblast expects to complete full enrolment by early third quarter.

17 Apr 2012

Imaxio closes EUR 2.9 million funding round

Imaxio, a biopharmaceutical company specialized in the areas of vaccines and genomics, announces today that it has finalized a funding round in which it raised EUR 2.9 million from its principal shareholder, Pradeyrol Developpement.

17 Apr 2012

Fluidigm begins direct service to customers in China

Fluidigm Corporation has begun direct service to customers in China. Through the establishment of a wholly-owned Fluidigm subsidiary in China in late January 2012, officially known as Fluidigm (Shanghai) Instrument Technology Co., Ltd..

16 Apr 2012

MDI to advance Detect-Ready MRSA Panel with $1.9M Series B recapitalization financing

Molecular Detection Inc., a company developing Detect-Ready® tests designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has completed a $1.9 million Series B recapitalization financing.

16 Apr 2012

Valeant acquires Pedinol Pharmacal

Valeant Pharmaceuticals International, Inc. announced today that Valeant has acquired Pedinol Pharmacal, Inc., a podiatry-focused, privately-owned specialty pharmaceutical company based in the U.S., for less than 1.5 times sales.

12 Apr 2012

C3BS' new production facilities in Mont-Saint-Guibert granted GMP Certification

The Belgian biotechnology company Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces that it has been granted Good Manufacturing Practice (GMP) Certification for its new production facilities in Mont-Saint-Guibert.

12 Apr 2012

Gerresheimer first quarter revenues increase 13.6% to EUR 268.8m

Gerresheimer has experienced particularly strong growth in revenues in the first quarter of the 2012 financial year.

12 Apr 2012

ArQule prices underwritten public offering of 7,150,000 shares of common stock

ArQule, Inc. today announced the pricing of an underwritten public offering of 7,150,000 shares of its common stock at a price of $7.30 per share.

12 Apr 2012

Emdeon, MZIHC enter services agreement

MZI HealthCare, LLC (MZIHC), a leading provider of health plan administration software, announced today that it has entered into a services agreement with Emdeon, a leading provider of revenue and payment cycle management and clinical information exchange solutions.

12 Apr 2012

Biomet third quarter net sales increase 5% to $708.9 million

Biomet, Inc. announced today financial results for its third fiscal quarter ended February 29, 2012.

12 Apr 2012

Takeda enters definitive agreement to acquire URL Pharma

Takeda Pharmaceutical Company Limited and URL Pharma Inc. jointly announced that Takeda's wholly-owned subsidiary, Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma – a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments.

12 Apr 2012

Nolato announces acquisition of Cope Allman Jaycare

As part of the Nolato Group's strategic expansion within medical technology and pharmaceuticals, Nolato has acquired the British company Cope Allman Jaycare for an initial purchase price of SEK 179 million (enterprise value) and a deferred consideration based on earnings up to and including the first quarter of 2014.

11 Apr 2012

Amgen enters agreement to acquire KAI Pharmaceuticals

Amgen and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.

11 Apr 2012

Simulations Plus second quarter net sales increase 6.4% to $2.789M

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its second quarter of fiscal year 2012 ended February 29, 2012.

11 Apr 2012

3M announces acquisition of CodeRyte

3M announced today that it has acquired CodeRyte Inc., an industry leader in clinical natural language processing (NLP) technology and computer-assisted coding solutions for healthcare outpatient providers.

11 Apr 2012

Genstar Capital enters definitive agreement to acquire ERT

eResearchTechnology, Inc. (ERT), a global technology-driven provider of health outcomes research services to biopharmaceutical sponsors and contract research organizations (CROs), today announced that it has entered into a definitive agreement to be acquired by affiliates of Genstar Capital LLC, a leading middle market private equity firm for $8.00 per share in cash in a transaction valued at approximately $400 million.

10 Apr 2012

Proteonomix provides corporate and clinical trial updates

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today provided updates on its progress.

10 Apr 2012

Affiliate of Sun Capital acquires CornerStone

Sun Capital Partners, Inc., a leading private investment firm specializing in leveraged buyouts and investments in market-leading companies, today announced that an affiliate has acquired CornerStone Research & Development, Inc., a leading global contract manufacturer of top-branded vitamins and dietary supplements, from Mitsui & Co. (U.S.A.), Inc.

10 Apr 2012